Terumo Corporation Reports Strong Fiscal Year 2025 Results

Terumo ( (TRUMF) ) has released its Q4 earnings. Here is a breakdown of the information Terumo presented to its investors.

Terumo Corporation, a leading medical technology company listed on the Tokyo Stock Exchange, specializes in providing innovative healthcare solutions across various sectors, including cardiac and vascular, medical care solutions, and blood and cell technologies. The company reported robust financial performance for the fiscal year ending March 31, 2025, with significant growth in revenue and profits. Terumo’s revenue increased by 12.4% to ¥1,036.2 billion, driven by strong sales in the Americas and Europe, and a favorable foreign exchange environment. The company’s adjusted operating profit surged by 29.8% to ¥203.4 billion, reflecting higher gross profit margins and strategic business expansions. The Cardiac and Vascular Company led the growth, with a 12.4% increase in revenue, supported by advancements in interventional systems and neurovascular devices. Meanwhile, the Blood and Cell Technologies Company experienced a 19.0% revenue boost, propelled by innovations in plasma and blood collection systems. Looking ahead, Terumo anticipates continued revenue growth and operational improvements, particularly in Europe and the United States, as it navigates challenges such as raw material costs and tariff uncertainties. The company remains committed to its 5-Year Growth Strategy, focusing on enhancing healthcare solutions and addressing industry challenges.